Think of Leqvio as a Niche Med for Lowering LDL

February 2022

Rx Leqvio (inclisiran) will be the first “small interfering RNA” therapy for lowering cholesterol.

This injectable works at a different step in the same pathway as the PCSK9 inhibitors, Praluent (alirocumab) and Repatha (evolocumab).

Leqvio prevents formation of the PCSK9 protein...Praluent and Repatha prevent PCSK9 binding. All of them increase LDL receptors in the liver and clearing of LDL cholesterol from the blood.


Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote